Compare Bumi Teknokultura Unggul Tbk (BTEK) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumi Teknokultura Unggul Tbk vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Bumi Teknokultura Unggul Tbk trades at Rp10 (market cap 462.77B, 42.64M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp246 (market cap 167.37B, 71K 24h volume). The key difference: Bumi Teknokultura Unggul Tbk is far larger — about 2.8× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Bumi Teknokultura Unggul Tbk is more actively traded (42.64M versus 71K). Which is the better fit depends on your goals.
| BTEK | OBAT | |
|---|---|---|
Market Cap | 462.77B | 167.37B |
Volume | 42.64M | 71K |
Lot | 426.36K | 710 |
Turnover | 454.59M | 17.51M |
Average Price | 10.66 | 246.63 |
Value | 454.59M | 17.51M |
Indicative Equilibrium Price | 10 | 246 |
Indicative Equilibrium Volume | 90.22K | 1 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumi Teknokultura Unggul Tbk
PT Bumi Teknokultura Unggul Tbk (the Company) was established based on notarial deed No.12 dated June 6, 2001 of Rusman, SH., notary in Jakarta. The Minister of Justice of the Republic of Indonesia approved the deed of establishment in his decision dated April 23, 2002 and was published in the State Gazette of the Republic of Indonesia No.80 Supplement No.9565 dated Oct 7, 2003. The latest changes in the articles of association of the Company was based on notarial deed No.51 dated October 21, 2003 of Rini Yulianti SH, notary in Jakarta, regarding with public offering.
Read more on BTEK →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
